Search Results
Your search for ,New matches 16913 pages
Showing 7501 - 7550What We Remember: From D-Day to Cancer Care
I RECENTLY returned from Normandy, France, where my wife and I attended events honoring the 75th Anniversary of D-Day and the millions, including close friends and family, who fought and died in the Second World War. My wife and a journalist from Los Angeles laid a wreath on Omaha Beach in honor of ...
EHA 2019: CLL12 Trial Investigates Ibrutinib in Previously Untreated, Asymptomatic Early-Stage CLL
At the 24th Annual Congress of the European Hematology Association (EHA), Langerbeins et al presented findings from the phase III CLL12 trial, which evaluated whether ibrutinib prolongs event-free survival in patients with previously untreated, Binet stage A chronic lymphocytic leukemia (CLL)...
FDA Expands Indications for Pembrolizumab to Include Metastatic SCLC With Disease Progression on or After Other Therapies
On June 17, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the anti–programmed cell death protein 1 (PD-1) therapy pembrolizumab (Keytruda) as monotherapy for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease...
Radiotherapy Increases Adverse Cardiovascular Event Risk for Patients With Lung Cancer
A new retrospective study led by investigators from Brigham and Women’s Hospital and Dana-Farber Cancer Institute examined outcomes for patients after receiving treatment for locally advanced non–small cell lung cancer (NSCLC), finding that the average radiation dose delivered to the...
Cytoreductive Surgery for Primary Central Nervous System Lymphoma
Through a systematic review of published studies, researchers report they have identified a distinct subtype of primary central nervous system (PCNS) lymphoma that should be considered for surgical removal, suggesting a major shift in how this type of tumor is evaluated and managed. These findings...
QuANTUM-R: Quizartinib vs Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD–Positive AML
In the phase III QuANTUM-R trial reported in The Lancet Oncology, Cortes et al found that the FLT3 inhibitor quizartinib produced a modest but significant improvement in overall survival vs salvage chemotherapy in relapsed or refractory FLT3 internal tandem duplication (FLT3-ITD)-positive acute...
KEYNOTE-001: 5-Year Overall Survival With Pembrolizumab in Advanced NSCLC
Long-term follow-up of the phase I KEYNOTE-001 study reported in the Journal of Clinical Oncology by Garon et al showed that pembrolizumab monotherapy was associated with an estimated 5-year overall survival of 23.2% for treatment-naive patients and 15.5% for previously treated patients with...
MAIA Trial: Addition of Daratumumab to Lenalidomide/Dexamethasone in Untreated Myeloma Ineligible for ASCT
In the phase III MAIA trial reported in The New England Journal of Medicine, Facon et al found that the addition of daratumumab to lenalidomide/dexamethasone significantly improved progression-free survival in previously untreated multiple myeloma ineligible for autologous stem cell transplantation ...
FDA Approves New Trastuzumab Biosimilar
Today, the U.S. Food and Drug Administration (FDA) approved trastuzumab-anns (Kanjinti) for all approved indications of the reference product trastuzumab (Herceptin): for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal...
FDA Pipeline: Designations and Reviews in Myelofibrosis, Myelodysplastic Syndromes, Biliary Tract Cancer, and T-Cell Receptor Therapy
Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for momelotinib in myelofibrosis, granted Priority Review to a biologics license application for luspatercept in myelodyslastic syndromes and beta-thalassemia, granted Orphan Drug designation for a new chemical...
2019 ASCO: OPTiM Study on T-VEC for Unresectable Melanoma
New research on the immunotherapy talimogene laherparepvec (T-VEC)—an injectable oncolytic virus—for patients with unresectable melanoma was presented by Milhem et al at the 2019 ASCO Annual Meeting (Abstract 9524). Researchers reported the ad hoc analysis of progression-free survival...
2019 ASCO: Pancreatic, Urothelial, and Cervical Cancers
In this episode, we discuss more news from the ASCO Annual Meeting, sharing interviews with experts on studies in pancreatic, urothelial, and cervical cancers. We’ll also tell you about a couple of new drug approvals announced this week by the FDA.
Survival Improvements for AYA Survivors Undermined by Late-Stage Diagnosis, Racial and Socioeconomic Disparities
The 2006 publication of the National Cancer Institute’s report Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults With Cancer highlighted the lack of improvement in cancer survival among people between the ages of 15 and 39 compared to children and older adults...
2019 ASCO: Long-Term Survival With Dabrafenib Plus Trametinib in Metastatic BRAF-Mutated Melanoma
In an extended analysis of the COMBI-d and COMBI-v trials reported at the 2019 ASCO Annual Meeting (Abstract 9507) and in The New England Journal of Medicine, Robert et al found a 5-year overall survival rate of 34% with the combination of dabrafenib and trametinib in previously untreated...
2019 ASCO: New TAILORx Data Provide Treatment Guidance for Women Under 50 With Early Breast Cancer
New information about adjuvant therapy to prevent recurrence of breast cancer in women 50 years of age or younger has emerged from the Trial Assigning Individualized Options for Treatment (Rx), or TAILORx. An analysis of a prespecified secondary endpoint in this trial found that an assessment of a ...
Christopher Sweeney, MBBS, and Ian D. Davis, MBBS, PhD, on ANZUP: Taking a Multidisciplinary Approach to Prostate, Kidney, Bladder, Testicular, and Penile Cancers
Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Ian D. Davis, MBBS, PhD, of Monash University and Eastern Health, discuss the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, working globally to speed clinical research in and treatment of urogenital cancers.
2019 ASCO: TOPARP-B Finds Olaparib Shows Efficacy in Men With BRCA-Mutant Prostate Cancer
The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib may benefit some men with prostate cancer, according to findings from the phase II TOPARP-B trial presented by Mateo et al at the 2019 ASCO Annual Meeting (Abstract 5005). Olaparib previously showed activity against metastatic...
2019 ASCO: Combination Therapy With SurVaxM in Newly Diagnosed Glioblastoma
Ahluwalia et al shared research results on SurVaxM at the 2019 ASCO Annual Meeting, reporting that combination therapy with the immunotherapy vaccine was more effective than standard therapy for nearly all patients with newly diagnosed glioblastoma in a phase II trial (Abstract 2016). SurVaxM...
Medicaid Expansion and Colorectal Cancer Screening
A new study examining Medicaid expansion and cancer screening found that the five states and District of Columbia that first adopted Medicaid expansion saw larger increases in colorectal cancer screening than states that did not expand Medicaid. The study—published by Fedewa et al in...
2019 ASCO: CLL14 Trial Evaluates First-Line Venetoclax/Obinutuzumab in Previously Untreated CLL
The phase III CLL14 trial—reported by Fischer et al at the 2019 ASCO Annual Meeting (Abstract 7502) and in The New England Journal of Medicine—found that the BCL2 inhibitor venetoclax plus the monoclonal antibody obinutuzumab prolonged progression-free survival vs obinutuzumab and...
2019 ASCO: Subgroups of Patients With Low-Grade Glioma May Benefit From PCV Chemotherapy Plus Radiotherapy
A recent, updated predictive analysis of the three World Health Organization (WHO)-defined molecular subgroups based on IDH mutation status and 1p/19q codeletion status represented in the high-risk treatment arms of a phase III trial found that both IDH-mutant subgroups may derive benefit ...
NCI Annual Report to the Nation on the Status of Cancer
The latest Annual Report to the Nation on the Status of Cancer finds that, for all cancer sites combined, cancer death rates continued to decline in men, women, and children in the United States from 1999 to 2016. Overall cancer incidence rates, or rates of new cancers, decreased in men from 2008...
First Full-Time Cancer Center to Serve Members of Navajo Nation
Leaders of the Navajo Nation, the Tuba City Regional Health Care Corporation (Tuba City), and the Cancer Support Community (CSC) joined Jill Biden, EdD, on the Navajo Nation in the opening of the first full-time cancer center on an American Indian reservation. The culturally adapted cancer care...
Latest Practice to Join OneOncology: Arizona Blood & Cancer Specialists
OneOncology, the national partnership of independent community oncologists, announced that it is entering into a new partnership with Arizona Blood & Cancer Specialists. The new practice will be the fourth to join OneOncology, a network already comprising 227 physicians practicing at 62 sites...
Memorial Sloan Kettering Unveils New Site on Long Island
Memorial Sloan Kettering Cancer Center (MSK) announced its commitment to communities across Long Island with the dedication of MSK Nassau, an outpatient cancer treatment facility centrally located in Nassau County, New York. MSK’s newest location, and its third on Long Island, opened for patient...
NCI Approves John Theurer Cancer Center as Member of Research Consortium
John Theurer Cancer Center, part of Hackensack Meridian Health Hackensack University Medical Center and a leading cancer institution in the New York/New Jersey metropolitan area, announced recently that it received approval from the National Cancer Institute (NCI) as a research consortium member of ...
Cornelis J.M. Melief, MD, PhD, Honored With AACR-CRI Award in Cancer Immunology
The American Association for Cancer Research (AACR) has recognized Cornelis J.M. Melief, MD, PhD, with the seventh AACR–Cancer Research Institute (CRI) Lloyd J. Old Award in Cancer Immunology. Dr. Melief is Emeritus Professor at the Leiden University Medical Center in the Netherlands, as well as...
Ronald Walters, MD, and Ruth O’Regan, MD, Elected to NCCN Board of Directors
The National Comprehensive Cancer Network® (NCCN®) recently announced the election of Ronald Walters, MD, to the role of Chair of the Board of Directors and Ruth O’Regan, MD, was named Vice Chair. Dr. Walters is Associate Head for the Institute for Cancer Care Innovation and a breast cancer...
From Leeches to Liquid Biopsy: Uncovering the Mysteries of Blood
BOOKMARK Title: Nine Pints: A Journey Through the Money, Medicine, and Mysteries of BloodAuthor: Rose GeorgePublisher: Metropolitan BooksPublication date: October 2018Price: $27.00, hardcover, 368 pages Blood has been mythologized and misunderstood since the earliest records of humankind and still ...
Scientist, Father of A Child With Autism Pushes Back on the Antivaccine Movement
BOOKMARK Title: Vaccines Did Not Cause Rachel’s Autism: My Journey as a Vaccine Scientist, Pediatrician, and Autism DadAuthor: Peter J. Hotez, MD, PhDPublisher: Johns Hopkins University PressPublication date: October 2018Price: $22.95, hardcover; 240 pages English physician Edward Jenner invented...
Actively Recruiting Clinical Trials Focused on Novel Drug Combinations for Gallbladder and Biliary Tract Cancers
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies that are focused on novel drug regimens in gallbladder and biliary tract cancers. These trials are attempting to determine the best dosages, side-effect profiles, and effectiveness of new...
Selected Abstracts From the 2019 ASCO Annual Meeting
To complement The ASCO Post’s comprehensive coverage of the 2019 ASCO Annual Meeting, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens for plasma cell dyscrasias, particularly multiple myeloma. For full details of these study abstracts, visit ...
2019 ASCO: NEOSTAR: Neoadjuvant Nivolumab Plus Ipilimumab in Early-Stage, Resectable NSCLC
Neoadjuvant treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response rate of 33% of treated patients with early-stage, resectable non–small cell lung cancer (NSCLC). With these results, the combination immunotherapy met the prespecified trial...
Aspirin Use and Cancer Prevention: Long-Term Data Needed on Benefits and Risks
In addition to its well-known cardioprotective benefits, aspirin has a substantial body of observational, preclinical, and clinical evidence supporting its efficacy in preventing cancer, most strongly for colorectal cancer.1 The strength of this evidence led the U.S. Preventive Services Task...
New: ASCO Answers Fact Sheet on Fertility and Cancer Treatment for Your Patients
Cancer and cancer treatment can cause infertility in both men and women. Prepare your patients for this possibility by giving them the ASCO Answers fact sheet titled Your Fertility and Cancer Treatment. This fact sheet covers: An overview of what fertility and infertility mean Which cancer...
New Content Collection in JCO Clinical Cancer Informatics Delves Into the Field of Mathematical Oncology
Mathematics, modeling, and simulation to study cancer are topics covered in a new special series in JCO Clinical Cancer Informatics (JCO CCI). On April 24, JCO CCI published its fourth special collection of articles, “Mathematical Oncology,” which showcases the current state of the field and new...
Experience the Next Breakthrough in Cancer Care
On the heels of the ASCO Annual Meeting in Chicago, ASCO is working with leading oncology societies in Thailand, China, Japan, South Korea, and others to convene the world of oncology in Asia. It has been my privilege to serve as Chair of the Co-Host Committee for ASCO’s newest and groundbreaking...
Engage With CENTRA: ASCO’s Center for Research and Analytics
In 2017, ASCO announced the launch of its Center for Research and Analytics (CENTRA). CENTRA’s mission is to conquer cancer by generating, integrating, analyzing, and sharing oncology data to foster innovation in research and patient care. CENTRA aims to make its cancer data available to the...
New Infographic, Commentaries Highlight Role of Opioids in Managing Cancer-Related Pain
As part of ASCO’s State of Cancer Care in America initiative, the Journal of Oncology Practice recently published an infographic about opioids and cancer pain, which highlights the specific needs of patients with cancer and some of the hurdles they face in trying to access prescribed opioids to...
Northern New England Clinical Oncology Society Supports 2019 International Development and Education Award and Merit Awards
The Northern New England Clinical Oncology Society (NNECOS) is a tristate regional affiliate of ASCO serving oncology practices within Maine, New Hampshire, and Vermont. A long-time supporter of Conquer Cancer®, the ASCO Foundation, and its Young Investigator Award (YIA) program, NNECOS expanded...
Expert Point of View: Kristin Higgins, MD
The discussant of the abstract on the use of prophylactic cranial irradiation in patients with extensive-stage small-cell lung cancer (SCLC), Kristin Higgins, MD, underscored the marked shift in practice patterns in the United States. However, she noted that many questions remain concerning...
Ruxolitinib Approved for Acute Graft-vs-Host Disease
On May 24, the U.S. Food and Drug Administration (FDA) approved ruxolitinib (Jakafi) for steroid-refractory acute graft-vs-host disease (GVHD) in adult and pediatric patients 12 years and older. Approval was based on the REACH1 trial/Study INCB 18424-271, an open-label, single-arm, multicenter...
Two Pediatric Trials Find Targets for Treatment-Refractory Cancers
An interim analysis of the large Pediatric MATCH trial found that 24% of children and young adolescents with cancers refractory to current treatments had been assigned to treatment with investigational targeted study agents based on genetic alterations detected in their tumors,1 which is more than...
How Have We Got It So Wrong?
The past 20 years have seen an unprecedented increase in the development of effective drugs for the management of cancer. The advent of immunotherapy offers even the promise of cure for some previously highly resistant diseases. The science is brilliant, the need is ever increasing—but the cost is ...
ACA Increases Access to Health Care, Early Diagnosis, and Timely Treatment for Patients With Cancer
The evidence is in: the Affordable Care Act (ACA) has enabled improved access to earlier diagnosis, earlier care, and reduced racial disparities in access to care for patients with cancer, according to two studies presented at the 2019 ASCO Annual Meeting. In states that adopted Medicaid...
MONALEESA-7 Shows Overall Survival Benefit for Ribociclib/Endocrine Therapy
The first statistically significant overall survival benefit has been shown for a cyclin-dependent kinase (CDK) 4/6 inhibitor plus endocrine therapy as first-line treatment of advanced breast cancer. The results are from the phase III MONALEESA-7 trial, which evaluated ribociclib plus endocrine...
First-Line Ibrutinib and Venetoclax for High-Risk and Older Patients With Previously Untreated CLL
In a single-center phase II trial reported in The New England Journal of Medicine, Jain et al found that the combination of ibrutinib and venetoclax was highly active in previously untreated high-risk and older patients with chronic lymphocytic leukemia (CLL). In the study, 80 patients...
2019 ASCO: Pain Management Program for Patients Undergoing Robotic Urologic Surgery
A specialized pain management program for patients who underwent robotic surgery for urologic cancers resulted in 8% of patients going home with narcotics after discharge, compared to 100% who would have received them without this enhanced recovery protocol. The group of patients...
2019 ASCO: Rituximab, Lenalidomide, and Ibrutinib Prior to Chemotherapy in DLBCL
Results of the phase II Smart Start trial revealed that combination targeted therapy consisting of rituximab, lenalidomide, and ibrutinib had an 84.6% overall response rate (ORR) and 38.5% complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a...
SARC024: Regorafenib in Metastatic Osteosarcoma
In the phase II SARC024 trial in sarcoma subtypes reported in the Journal of Clinical Oncology, Davis and colleagues found that regorafenib improved progression-free survival vs placebo in the cohort of patients with metastatic osteosarcoma. The double-blind study included 42 patients from 12 U.S. ...
